UY36455A - Antagonistas del receptor ep3 de prostaglandinas - Google Patents
Antagonistas del receptor ep3 de prostaglandinasInfo
- Publication number
- UY36455A UY36455A UY0001036455A UY36455A UY36455A UY 36455 A UY36455 A UY 36455A UY 0001036455 A UY0001036455 A UY 0001036455A UY 36455 A UY36455 A UY 36455A UY 36455 A UY36455 A UY 36455A
- Authority
- UY
- Uruguay
- Prior art keywords
- prostaglandinas
- antagonists
- receiver antagonists
- receiver
- prostaglandin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente, se proporcionan antagonistas del receptor EP33 de prostaglandinas, procesos para preparar dichos antagonistas y métodos que comprenden la administración de dichos antagonistas a un mamífero que lo necesita.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462095337P | 2014-12-22 | 2014-12-22 | |
US201562259528P | 2015-11-24 | 2015-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36455A true UY36455A (es) | 2016-07-29 |
Family
ID=55077554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036455A UY36455A (es) | 2014-12-22 | 2015-12-18 | Antagonistas del receptor ep3 de prostaglandinas |
Country Status (7)
Country | Link |
---|---|
US (1) | US9738626B2 (es) |
EP (1) | EP3237401B1 (es) |
JP (1) | JP2017538769A (es) |
CA (1) | CA2915470A1 (es) |
TW (1) | TW201632513A (es) |
UY (1) | UY36455A (es) |
WO (1) | WO2016103097A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10336701B2 (en) | 2017-08-10 | 2019-07-02 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists |
US10590083B2 (en) | 2017-08-10 | 2020-03-17 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists |
US10399944B2 (en) | 2017-08-10 | 2019-09-03 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists |
CA3100221A1 (en) | 2018-05-17 | 2019-11-21 | Bayer Aktiengesellschaft | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
WO2022215072A2 (en) | 2021-04-07 | 2022-10-13 | Hadasit Medical Research Services & Development Ltd. | Therapeutic modalities for inhibiting pancreatic beta cell impairment and treating diabetes |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4219483A (en) | 1978-09-11 | 1980-08-26 | Pfizer Inc. | 4-Pyrone prostaglandin antagonists |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
SK18822000A3 (sk) | 1998-07-06 | 2001-12-03 | Bristol-Myers Squibb Company | Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
MXPA03007785A (es) | 2001-02-28 | 2003-12-08 | Merck & Co Inc | Derivados de piperidina acilados como agonistas del receptor de melanocortina 4. |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
EA200400980A1 (ru) | 2002-02-27 | 2005-02-24 | Пфайзер Продактс Инк. | Ингибиторы асс |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
PT1753748E (pt) | 2004-05-12 | 2009-08-28 | Pfizer Prod Inc | Derivados de prolina e a sua utilização como inibidores de dipeptidil peptidase iv |
AU2005247693A1 (en) | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Tetraazabenzo[E]azulene derivatives and analogs thereof |
BRPI0514611A (pt) | 2004-08-26 | 2008-06-17 | Actelion Pharmaceuticals Ltd | uso de um composto, compostos, e, medicamento |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
US20080200568A1 (en) | 2005-08-30 | 2008-08-21 | Stephanie Chissoe | Genes Associated With Type ll Diabetes Mellitus |
EP2463283B1 (en) | 2006-04-20 | 2014-06-11 | Pfizer Products Inc. | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
JP2010511035A (ja) | 2006-11-29 | 2010-04-08 | ファイザー・プロダクツ・インク | スピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
EA200901381A1 (ru) | 2007-05-10 | 2010-06-30 | Пфайзер Лимитед | Производные азетидина и их применение в качестве антагонистов простагландина е2 |
ATE540954T1 (de) | 2007-05-11 | 2012-01-15 | Pfizer | Aminoheterocyclische verbindungen |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
ES2545231T3 (es) | 2008-05-28 | 2015-09-09 | Pfizer Inc. | Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa |
EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
CA2729581A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
RS52236B (en) | 2008-08-28 | 2012-10-31 | Pfizer Inc. | DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA |
TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
WO2010103438A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
AU2010222589B2 (en) | 2009-03-11 | 2012-08-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
WO2010128425A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
CN102459222B (zh) | 2009-06-05 | 2014-06-04 | 辉瑞大药厂 | 用作gpr119 调节剂的l-(哌啶-4-基)-吡唑衍生物 |
WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
CN103391941A (zh) | 2011-02-23 | 2013-11-13 | 辉瑞大药厂 | 用于治疗神经障碍的咪唑并[5,1-f][1,2,4]三嗪类 |
MX2013014470A (es) | 2011-06-07 | 2014-03-21 | Pfizer | Compuestos de pirazolo[3,4-d]pirimidina y su uso como inhibidores pde2 y/o inhibidores cyp3a4. |
JP6348582B2 (ja) * | 2013-10-09 | 2018-06-27 | ファイザー・インク | プロスタグランジンep3受容体の拮抗薬 |
-
2015
- 2015-12-11 WO PCT/IB2015/059548 patent/WO2016103097A1/en active Application Filing
- 2015-12-11 JP JP2017533416A patent/JP2017538769A/ja not_active Withdrawn
- 2015-12-11 EP EP15821169.8A patent/EP3237401B1/en not_active Not-in-force
- 2015-12-16 US US14/970,930 patent/US9738626B2/en not_active Expired - Fee Related
- 2015-12-17 TW TW104142513A patent/TW201632513A/zh unknown
- 2015-12-17 CA CA2915470A patent/CA2915470A1/en not_active Abandoned
- 2015-12-18 UY UY0001036455A patent/UY36455A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2017538769A (ja) | 2017-12-28 |
CA2915470A1 (en) | 2016-06-22 |
US20160176851A1 (en) | 2016-06-23 |
EP3237401A1 (en) | 2017-11-01 |
US9738626B2 (en) | 2017-08-22 |
EP3237401B1 (en) | 2019-03-06 |
TW201632513A (zh) | 2016-09-16 |
WO2016103097A1 (en) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36455A (es) | Antagonistas del receptor ep3 de prostaglandinas | |
CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
DOP2016000224A (es) | Tratamientos combinados con anticuerpos anti-cd38 | |
DOP2017000124A (es) | Agonistas parciales del receptor de insulina | |
TWD170114S (zh) | 腳踏車座墊(二) | |
TWD171866S (zh) | 腳踏車座墊(一) | |
UY35776A (es) | ?antagonistas de receptor ep3 de prostaglandina?. | |
UY34682A (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina. | |
BR112016017402A2 (pt) | fusões anti-pcsk9~glp-1 e métodos para uso | |
TWD173762S (zh) | 自行車用頭燈 | |
CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
CL2016002469A1 (es) | Sulfamidasa modificada y su producción | |
GT201400061S (es) | Diseño de motocicleta | |
DOP2017000264A (es) | Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio | |
TWD175782S (zh) | 緩衝器 | |
UA98443U (ru) | Применение коллоидно-изоосмолярная раствора волювен как средства для улучшения перфузии головного мозга при ишемии | |
CO7091168A2 (es) | Tensor para unir elementos estructurales | |
TWD168844S (zh) | 運動用墊 | |
CR20150630S (es) | Motocicleta | |
CO7051029A2 (es) | Proceso para la preparacion de fenilpropanonas sustituidas | |
TWD162428S (zh) | 鞋墊 | |
TN2014000384A1 (fr) | نظام صوتي ذكي وآمن | |
TH1401004274B (th) | อุปกรณ์การล็อกที่นั่งของรถจักรยานยนต์ | |
TWD164930S (zh) | 研磨機 | |
TWD164209S (zh) | 澡盆 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20220721 |